Implants are promising for long-term, sustained, and reversible delivery of ARV drugs that may bypass adherence challenges for end users.
Leah M. Johnson, PhD
Advertisement
Articles by Leah M. Johnson, PhD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Contagion Live
1
FDA Approves Ensitrelvir as First Oral Post-Exposure Prevention Option for COVID-19
2
Migration Trends Demonstrate Rare, But Increasing Malaria Cases in New York City
3
PolyPid Completes FDA NDA Submission for D-PLEX100 in Surgical Site Infection Prevention
4
Post-Exposure Protocol for STDs Prompts Resistant Gonorrhea
5